New Treatments & Clinical Trials for Pulmonary Arterial Hypertension

Pulmonary arterial hypertension is a rare disease where blood pressure in the lung arteries rises dangerously high, straining the heart's right side. About 500 to 1,000 people in the US are diagnosed each year. Current treatments include prostacyclin pathway drugs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, often used in combination to keep symptoms manageable.

What's actually going on in research

Trials are testing sotatercept, a drug that targets abnormal cell growth in artery walls and was FDA-approved in 2024. Researchers are studying ways to reverse artery damage rather than just dilate vessels, testing stem cell therapies, and looking at earlier intervention before the heart weakens. Gene therapy and drugs targeting inflammation pathways are also in development.

What to know before you search

Eligibility typically depends on PAH type, severity measured by walk distance and heart function, current medications, and whether other lung or heart conditions are present.

What types of trials are currently open

• Add-on treatment trials — Testing new drugs added to standard PAH medications to see if they further improve exercise tolerance and slow disease progression.
• Monotherapy trials — Testing whether a single new drug works well enough on its own, particularly in people newly diagnosed with milder disease.
• Combination strategy trials — Comparing different combinations of PAH drugs to find which work best together and when to add them.
• Stem cell trials — Studies testing whether stem cells can repair damaged lung arteries or help the heart adapt to high pressure.
• Device and surgical trials — Testing devices that reduce pressure between heart chambers or comparing lung transplant approaches.